Recent Updates — CSCIF

COSCIENS Biopharma Inc. completed a two-step share capital amendment effective July 3, 2026. First, a consolidation occurred at a ratio of 1-for-150. Second, an immediate 50-for-1 stock split followed, resulting in a net reduction of shareholder interests by a factor of three. Shareholders holding fewer than 150 shares as of July 2, 2026, received a cash payment of US$1.60 per share. The company plans to file Form 15 on July 6, 2026, to suspend its SEC reporting obligations to reduce administrative costs. COSCIENS Biopharma Inc. is a biopharmaceutical company.